VHIRhttp://www.vhir.org/salapremsa/noticies/noticies_paginacio.asp?page=1&mv1=5&mv2=3es-esIRHUV15Great success of the 1s Innovation Day organized by ICS (05/03/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=38&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0038\2015_0038_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The experience “Preoperatorio online, enfermería y anestesia”, presentaded by Domingo Blanco, head of the Anesthesia Service at Viladecans Hospital has been awarded as the Best Innovative Experience of Catalan Institute of Health (ICS). This project develops a presurgery circuit, led by the nurse team at the Anesthesia Service, using the TIC to save duplicity of complementary trials and reduce movements of the patients. More than 600 people attended the 1st Innovation Day of ICS, that during all the morning have listened the 10 finalist proposals out of 388 accepted. 3 of them were from VHIR: "Neuroprotección como tratamiento de la retinopatía diabética: del modelo experimental al ensayo clínico", led by Dr. Rafael Simó, head of the Diabetes research group at VHIR and one of the winners of the first edition of VHIR Innovation Contest last year. "Desarrollo de una nueva plataforma de subtipificación de alta resolución y detección de infecciones mixtas y mutaciones de resistencia del virus de la hepatitis C", led by Dr. Joan Ignasi Esteban Mur, from the liver diseases group and "Programa de rehabilitación cardíaca y prevención secundaria en enfermos con síndrome coronaria aguda atendidos en el HUVH", led by Dr. Xavier Armengol, from the cardiocirculatory pathology group completed the presence of Vall d'Hebron researchers. On March 12 it will be the Opening of the Second VHIR innovation contest, that in this edition includes participants from other centers at ICS, Catalan centers of ITEMAS and Catalan centers accredited by ISCIII. </td></tr></table>comunica@vhir.org (VHIR)Thu, 5 Mar 2015 00:00:00 GMTDarrer adéu al Dr. Jordi Xercavins (04/03/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=37&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0037\2015_0037_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> El Dr. Jordi Xercavins, excap del servei de Ginecologia de l'Hospital Universitari Vall d'Hebron ens va deixar dilluns. L'acte de comiat tindrà lloc avui, a les 11.30 h al Monestir de Sant Cugat. Volem expressar el nostre sincer condol a la seva família i amics en aquests moments difícils, així com a tots els professionals que hi van treballar durant aquests anys. Jordi Xercavins Montosa va ser cap del Servei de Ginecologia des de l'any 1993 fins al 2013, quan es va jubilar i va passar a ser consultor sènior i catedràtic de Ginecologia i Obstetrícia de la Universitat Autònoma de Barcelona (UAB). Fins al 2013 també va ser president de la Secció de Ginecologia Oncològica i Patologia Mamària de la Societat Espanyola de Ginecologia i Obstetrícia. Més enllà de les grans contribucions que va realitzar al Servei de Ginecologia de l'Hospital, com ara la creació de les diferents subespecialitats que encara estan vigents, i l'aposta per la recerca i la docència, el Dr. Xercavins sempre va destacar per la seva gran qualitat humana i l'empatia que sempre demostrava vers tots el que el rodejaven. Descansi en pau. </td></tr></table>comunica@vhir.org (VHIR)Wed, 4 Mar 2015 00:00:00 GMTVHIR's Innovation Contest arrives to other research centers of Catalonia (03/03/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=36&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0036\2015_0036_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> On March 12, with a ceremony at 9.30h at the Sala d'Actes on the 10th Floor of the Àrea General at HUVH, will be the opining of the 2nd Innovation Contest. In this editiion the great news is that, after the success of the first edition, there will be participants from Hospitals and research centers belonging to ICS, Hospital research centers of Catalonia accredited by ISCIII and Hospital research centers of Catalonia that are part of ITEMAS. Organized by VHIR in collaboration with ACC10 and ROCHE Diagnostics, aims to promote the innovation that comes from hospitals and their associated research centres. With this initiative we aim to raise awareness about health innovation projects, in order to attract investors and companies. At the same time we support the projects in the first stages, where we will assess the technical viability and the market. In addition, we want to award the professionals for their innovation. All the participants can apply until 12th April with these conditions: Research projects with an industrial interest that culminate in the development of a prototype, Research projects with an industrial interest that culminate with a pre-clinical trial, Research that can include patents or development with companies, Ideas derived from care practices that create relevant solutions to society problems, Ideas, inventions and innovative actions which have been realised in hospitals (improvements in the available tools, in the processes, in the medical care, organizational structures,...). Projects that have already been transferred or involve companies that are going to license the project, are not allowed to apply. On May 5 there will be a Finalists’ announcement and then will begin a procedure of information, training and viability report that will finish with the final decision and the presentation awards on July 10. Finalists will receive training which will both guide their projects, and instruct them in specific aspects of knowledge transfer. Experts are consultancies and/or agents without any relation with VHIR. The Honorary jury is composed by: Departament de Salut and Departament d'Economia i Coneixement of the Catalan Government, Universitat Autònoma de Barcelona, Hospital Universitari Vall d'Hebron (HUVH), Vall d'Hebron Institute of Oncology (VHIO), Banc de Sang i Teixits and CERCA. <p style=" text-align: left; text-indent: 0px; padding: 0px 0px 0px 0px;</td></tr></table>comunica@vhir.org (VHIR)Tue, 3 Mar 2015 00:00:00 GMTDr. Ribó presents at the MWC advances in the follow up of stroke patients (02/03/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=34&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0034\2015_0034_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Marc Ribó, member of the research group in neurovascular diseases at VHIR and neurologist at the Ictus Unit of the HUVH, has been at the Barcelona Mobile World Congress (MWC) presenting, together with the Fundación Vodafone Spain, the new advances in the follow up of stroke patients at home under the control of a medical team Visited by the Major of Barcelona, Xavier Trias, and the Catalan Minister for Enterprise and Employment, Felip Puig, Dr. Ribó has explained in the stand of Vodafone the news methods that will improve the situation of stroke patients during the follow up phase at home. Thanks to this innovation, the doctor will send follow up exercises personalized and in multimedia format (text, picture and video depending on the patient), who will be able to do it from home. Doctors will supervise the evolution with videos recorded during the exercises made by patients. This new improvement in the project, that is still being validated, is a step forward of the Global Tele Rehabilitation System (GTRS), also promoted by VHIR with the help of Fundación Vodafone Spain, that finished with great results after one year and a half of testing applications. </td></tr></table>comunica@vhir.org (VHIR)Mon, 2 Mar 2015 00:00:00 GMTDr. Pedro Brugada talks about the syndrome that has his last name (02/03/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=32&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Doctor Pedro Brugada, responsible of the Heart Rhytm Management Centre of the Universitair Ziekenhuis in Brussels (Belgium), has visited the researchers and cardiologists at the Vall d’Hebron University Hospital to teach the session called ‘Past, present and future of the Brugada syndrome’. The physician, born in Banyoles (Girona), discovered in 1992 an alteration in the electrocardiogram of patients that had had a sudden death. Sometime later, thanks to the help of his brothers, also prestigious cardiologists, they named this particular lethal cardiac arrhythmia as ‘Brugada syndrome’. About this syndrome he spoke in the session organized by the Cardiology Service and in a short video where he explains why it isn’t an illness and what its prevalence is. During the visit at the center, Dr. Brugada also had time to discuss with the cardiologists at Vall d’Hebron some of the cases of patients admitted in the hospital. </td></tr></table>comunica@vhir.org (VHIR)Mon, 2 Mar 2015 00:00:00 GMTVHIR, committed to the research on rare diseases (27/02/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=33&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0033\2015_0033_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The 28th of February is Rare Disease Day with the theme “Day by Day, Hand in Hand”, to raise awareness about this diseases that, only in Spain, affect more than 3 million people. The Vall d’Hebron Institute of Research (VHIR) wants to join in the campaign to give patients and families a feeling of hope and the possibility of a positive change. Also, in Spain, the Spanish Federation of Rare Diseases (FEDER) has launched a campaign to commemorate the day and make these diseases visible. In consists on taking a photo with a green mark on the cheek and sharing it, as has done VHIR’s director, Dr. Joan Comella, and some of the researchers that work in rare diseases. They are Dr. Anna Meseguer, that together with Dr. Ariceta lead research work on Dent’s syndrome and&nbsp; hypomagnesaemia; Dr. Ramon Martí, in the area of mitochondrial diseases; and Dr. Cristina Solé, that works on lupus. The fight against rare diseases is one of VHIR’s pillars, where nearly 200 of these diseases are investigated, from 26 different clinical areas. Doctors, predoc and postdoc researchers, nurses and technical staff make a total of more than 350 professionals that dedicate part of their day by day to move forward in the knowledge of these diseases and finding treatments to increase quality of life of patients and cure them. For a better management of these diseases, the Vall d’Hebron University Hospital is starting up a new and integrated model of patient care, in which research has a key role. With the new system, most of these patients will be able to be visited in a module of the Rare Diseases Unit, by multidisciplinary teams trained in research and clinical treatment. In addition, the new model allows the possibility of a follow up and treatment of patients, from childhood to adulthood. The goal is that specialists can “reach an understanding through a case management system” to schedule visits with the frequency that is required in each case. This unit would be integrated in the Genetics clinical and molecular area, directed by Dr. Eduardo Tizzano, head of the Genetics Medicine group at VHIR. Among the rare diseases investigated at Vall d’Hebron, there are systemic diseases, such as lupus erythematosus, scleroderma and Sjörgen’s syndrome; pediatric neurology diseases, like mitochondrial diseases, lysosomal storage disorder or neuromuscular disorders; and other such as cystic fibrosis, Marfan syndrome, immunodeficiency diseases, spina bifida, ALS, or Dent’s disease. </td></tr></table>comunica@vhir.org (VHIR)Fri, 27 Feb 2015 00:00:00 GMTLa fundación Dexeus beca un proyecto sobre cáncer de ovario liderado en el VHIR (26/02/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=31&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0031\2015_0031_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> La Fundación Dexeus Salud de la Mujer ha concedido la beca de Ginecología Oncológica y Mamaria al grupo de Investigación Biomédica en Ginecología del Vall d’Hebron Institut de Recerca (VHIR), por el proyecto “Salivaomics; estrategia innovadora para la mejora del diagnóstico precoz del cáncer de ovario”. El objetivo del proyecto, liderado por la Dra. Silvia Cabrera, es identificar una serie de biomarcadores que permitan desarrollar un sistema para diagnosticar el cáncer de ovario en las etapas iniciales, a través de una muestra de saliva. Según la investigadora, "la existencia de métodos de diagnóstico que permitan detectar el cáncer de ovario en las etapas iniciales de la enfermedad, cambiaría radicalmente el índice de curación de las pacientes". Para llevarlo a cabo, los investigadores del VHIR realizarán una secuenciación masiva de la fracción de ARN libre presente en las muestras de saliva de pacientes en estadios iniciales (I-II) y avanzados (III-IV) de la enfermedad. Las muestras se recogerán en el quirófano del Servicio de Ginecología del Hospital Universitario Vall d’Hebron, por donde regularmente pasan las mujeres que se someten a una cirugía de resección, que es el último paso para diagnosticar el cáncer de ovario. El proyecto ha sido becado con 3.000 euros, tiene una duración prevista de dos años y cuenta con la colaboración del Dr. David T. Wong,&nbsp; líder mundial en el campo de la saliva ómica en el Center for Oral/ Head and Neck Oncology Research de la UCLA School of Dentistry, en Los Ángeles (EEUU). El objetivo es desarrollar a largo plazo un test de diagnóstico y/o cribado con la participación de un partner industrial. La creación de sistemas para detectar a tiempo el cáncer de ovario es vital, ya que actualmente, el 80% de las pacientes son diagnosticadas en los estados avanzados de la enfermedad (III-IV), donde la tasa de supervivencia a los 5 años está entre el 30-20%. En cambio, si la enfermedad se detecta precozmente (I-II), aumenta entre el 90-70%. El método de diagnóstico actual para el cáncer de ovario se basa en las siguientes pruebas: un examen pélvico, en el cual el ginecólogo puede palpar el tamaño y la consistencia de los ovarios; la determinación de los niveles séricos del marcador CA125, que está muy elevado en los estadios avanzados pero solo lo está en el 50% de los casos iniciales; una ecografía abdominal, que permite detectar masas sospechosas en los ovarios; y finalmente, la cirugía de resección, que es estrictamente necesaria para confirmar la enfermedad con e</td></tr></table>comunica@vhir.org (VHIR)Thu, 26 Feb 2015 00:00:00 GMTReconocimiento internacional para la enfermería del Hospital Vall d'Hebron (25/02/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=30&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0030\2015_0030_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> El Hospital Universitario Vall d’Hebron ha sido reconocido como Centro Comprometido con la Excelencia en Cuidados de Enfermería, una acreditación que reconoce el alto grado de calidad de su enfermería, por el compromiso de poner en marcha guías de buenas prácticas elaboradas por la prestigiosa Registered Nurses Association of Ontario (RNAO), la Asociación de Enfermeras de Ontario (Canadá), con más de 60.000 personas afiliadas, y un auténtico referente internacional en este ámbito profesional. La RNAO ha creado un programa llamado Best Practices Spotlight Organizations (BPSO) dedicado a la implementación de estas guías, coordinado en el Estado por el Investen-ISCIII. En este programa, Vall d’Hebron es el primer centro de Cataluña en conseguir esta acreditación, que también recibirán otros siete hospitales del Estado. Hasta el momento, lo han conseguido centros de todo el mundo como el Mount Sinai de Toronto o el St. Joseph’s Health Care London. El Hospital Universitario Vall d’Hebron ha conseguido la acreditación después de tres años de intenso trabajo que contado con la implicación de más de 150 profesionales de 16 unidades de las tres áreas en que se divide el Hospital. Con la participación en este programa, se han implantado y evaluado el impacto de dos guías de práctica clínica: Cuidado y manejo de la ostomía y Prevención de caídas y lesiones derivadas de las caídas en personas mayores. Las dos guías implementadas nacen de la investigación en cuidados. Está demostrado que las buenas prácticas en enfermería, no solo mejoran la atención a los y las pacientes, sino que contribuyen al ahorro de costes del sistema sanitario. La enfermería del Vall d'Hebron también investiga en el grupo de Cuidados de la Salud del VHIR, liderado por la Dra. Carmen Fuentelsaz. </td></tr></table>comunica@vhir.org (VHIR)Wed, 25 Feb 2015 00:00:00 GMTUse of massive genome sequencing to identify pathologic mutations (24/02/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=28&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0028\2015_0028_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> How work and how can be applied the massive sequencing techniques into biomedical research? Researchers from Vall d’Hebron Institute of Research (VHIR) and the Centre Nacional d’Anàlisi Genòmica (CNAG) answered this question at the course ‘Identification and analysis of sequence variants in sequencing projects: fundamentals and tools’, hosted at VHIR on February 11 and 18. The latest massive sequencing techniques belong to the field of genomics and are applied to biomedical research and for the diagnosis of patients. These techniques are able to identify the differences in the genome of individuals, and are used with the aim to promote the most accurate diagnosis, choose the best treatment or give genetic counseling on hereditary diseases. About these techniques talked Dr. Xavier de la Cruz, head of the Translational Bioinformatics group at VHIR, and Casandra Riera, researcher of the same group, and doctors Ivo Gut, Sergi Beltran and Sophia Derdak from CNAG. All the presentations of the course are available on Slideshare: Interpretation of sequence variants in the biomedical environment: what should we take into account, by Xavier de la Cruz Using and combining the different tools for predicting the pathogenicity of sequence variants, by Casandra Riera <p style=" text-align: left; text-indent</td></tr></table>comunica@vhir.org (VHIR)Tue, 24 Feb 2015 00:00:00 GMTVall d'Hebron Market rises 1,140€ for research in cardiovascular diseases (24/02/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=29&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0029\2015_0029_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The sellers of the stands of the Vall d’Hebron Market have raised 1,140€ with the solidarity 2015 calendar, sold by 1 euro. The promoters of the initiative have given today the funds raised to Dr. David García Dorado, head of the research group on Cardiovascular Diseases at Vall d’Hebron Institute of Research (VHIR). With this action the market workers wanted to do their bit in heart diseases research, as it causes thousands of deaths every year. The calendars were drown by Mario Tarragó and designed by Jordi Santamaria. The Cardiovascular Diseases group works in prevention, diagnosis and treatment of heart diseases. The researchers also coordinate actions in sanitary education, healthy lifestyle promotion and create new diagnosis and therapeutic tools and new care systems. </td></tr></table>comunica@vhir.org (VHIR)Tue, 24 Feb 2015 00:00:00 GMTRegistrations open for the 2nd edition of the Master's Degree in Translational Biomedical Research (23/02/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=27&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0027\2015_0027_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d’Hebron Institute of Research (VHIR), associated to the Universitat Autònoma de Barcelona, opens the registrations of the 2nd edition of the Master’s Degree in Translational Biomedical Research UAB-VHIR, which will start on October 2015. Registrations will be open until September 2015, but the first students will be admitted on April. As a new feature of this year’s edition, students will have to choose three out of the six optional subjects, taught by researchers and clinicians currently working at Vall d’Hebron University Hospital. The optional subjects are: Brain and Nervous Peripheral System Diseases; Cardiovascular and Kidney Diseases; Oncology Diseases; Liver and Digestive Diseases; Microbiology, Infectious Diseases and Critical Pathology; and Respiratory, Immune, Systemic and Endocrine System Diseases. The program will also offer new lessons on transversal competences, such as communication and outreach, business development, national and international calls, and project management. The aim of the master is to generate excellent young researchers by providing them with the necessary combination of scientific and medical knowledge and skills to contribute successfully to the future of translational medical research. It is addressed to research career, providing access to a PhD program related to the biomedicine area that the students had previously chosen for their training program and internship. In this regard, the master is an excellent occasion for working in a real laboratory with first-rate scientists. Finally, for the second consecutive year, students will have the chance to apply for a grant that will cover all the tuition and course costs. Last year 6 students were granted, but for this second edition the number of students granted has yet to be decided. Registration process </td></tr></table>comunica@vhir.org (VHIR)Mon, 23 Feb 2015 00:00:00 GMT"I wish music could tame cancer" (19/02/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=25&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0025\2015_0025_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Interview posted in the blog '30 anys, 30 veus' by the Catalan Institute of Health (ICS): Per a Josep Roma, tant en la música com en la lluita contra el càncer, cal posar-hi passió. Tot i que la seva faceta de músic va quedar aparcada quan va arribar a la universitat per estudiar medicina, mai ha deixat de tocar. Es defensa a la perfecció amb diversos instruments: el saxo, el clarinet, la tenora i fins i tot el tible, un instrument tradicional semblant a l’oboè. Quan surt del laboratori, troba temps per participar en concerts solidaris i actuacions d’estils musicals tan variats com la cançó francesa o el rock i, també, per cercar la “genètica de les notes”. Voleu saber què significa aquesta denominació? I quan la va “explicar”? Continueu llegint! Lloc de treball. Laboratori de Recerca Traslacional del Càncer en la Infància, Servei d’Oncologia i Hematologia Pediàtrica, Vall d’Hebron Institut de Recerca, Hospital Universitari Vall d’Hebron, Barcelona. Tens molts estudis de música… És cosa de família o una iniciativa pròpia? Bé, vaig fer estudis de música des de molt aviat i, realment, m’interessava molt la música des de molt petit. Probablement hi va influir el fet que el meu pare fos músic, també. Recordo que va arribar a les meves mans un saxo de joguina i em vaig posar a tocar cançons de seguida, tot i que era un instrument de plàstic. Els meus pares van quedar-se una mica sorpresos del que podia treure d’aquell instrument tan rudimentari i va ser el que els va fer decidir a apuntar-me a estudiar música immediatament, tot i que encara era molt petit: devia tenir 6 o 7 anys. El teu currículum musical és tan important com el professional. Quines inquietuds mouen un músic a formar part de grups amb estils musicals tan variats com la música tradicional, el rock, la cançó francesa o, fins i tot, a arribar a acompanyar, en alguna ocasió, cantants de primera línia, com ara la Núria Feliu? No crec que el currículum musical sigui tan gran, no m’hi he pogut dedicar gaire. La música, com tot, demana molt de temps d’estudi i, a partir de cert nivell, és necessari dedicar-hi moltes hores al dia. Al principi, em vaig agafar la carrera de música molt seriosament i compaginava sense gaires problemes la música i els estudis, però quan vaig arribar a la universitat l’exigència en els dos casos ja era massa gran per seguir amb les dues coses al cent per cent. Cap als darrers anys de carrera, vaig anar relaxant el tema de la música per anar-me centrant, gradualment, més en la ciència. I sí, he anat fent una mica de tot dintre de la música; és un privilegi haver-ho pogut fer perquè realment he après de totes les experiències i m’ho he passat molt bé en tots els casos. Tinc la sort que tots els estils de música m’agraden. Sempre dic que, de fet, només n’hi ha dos, d’estils: la música bona i la dolenta. Has participat en un congrés de pediatria on has ajuntat les seves dues facetes en una xerrada musical: “La genètica de les notes”. Quin plantejament et feies i què buscaves despertar entre els assistents? Això pretenia ser una sorpresa i, de fet, ho va ser perquè molta gent no tenia ni idea que jo toqués cap instrument ni, molt menys, que ho anés a fer en aquell moment. A més, l’any anterior havia fet una xerrada científica en el mateix congrés o sigui que poca gent es pensava qu</td></tr></table>comunica@vhir.org (VHIR)Thu, 19 Feb 2015 00:00:00 GMTDr. Josep Gámez participates in the 3rd Catalan Ataxias meeting (18/02/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=24&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0024\2015_0024_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Josep Gámez, head of the Peripheral Nervous System group at Vall d’Hebron Institute of Research (VHIR), was one of the lecturers of the III Catalan Ataxias meeting, organized by the Catalan Association for Ataxias, on January in Barcelona. VHIR researcher talked about the usefulness of functional rating scales for the assessment and follow-up of ataxias, which are a group of rare diseases characterized by a progressive spinal and/or cerebellar degeneration. The participants also discussed the latest studies and clinical trials on these diseases. Some of them were researchers and neurologists from Catalan hospitals such as Hospital Universitari Germans Trias i Pujol, Hospital Universitari de Bellvitge, Hospital Clínic, l’Hospital Sant Joan de Déu and Hospital Josep Trueta. The meeting was a perfect occasion for networking between patients, their relatives, researchers and clinicians. According to the Catalan Association for Ataxias, nearly 900 people are affected in Catalonia. Patients with ataxia use to have difficulties related to coordination, balance, speech, and can suffer heart problems.&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Wed, 18 Feb 2015 00:00:00 GMTVHIR researchers develop a methodology that will help doctors choosing the most efficient treatment for hepatitis C (16/02/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=23&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0023\2015_0023_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers from Vall d’Hebron Research Institute (VHIR) have developed a new deep sequencing methodology that accurately classifies the 7 confirmed genotypes of the hepatitis C (HCV) virus, and the different subtypes. The new system also allows, for the first time, to identify infections with more than one subtype of the virus (mixed infections), the variability of the virus and possible resistance mutations. “We are going one step further in personalized medicine, because thanks to this new system we can decide which is the treatment with greater chances of success in each patient”, reports Dr. Rafael Estaban Mur, head of the Hepatic Diseases group at VHIR and responsible of the Department of Internal Medicine and Hepatology at Vall d’Hebron University Hospital. The two commercial available genotyping methods can only identify the main genotypes and two out of the 67 subtypes of the virus. As the efficacy of new treatments depends on the subtype, physicians do not have tools to choose the most efficient treatment. The study, published in the Journal of Clinical Microbiology, is a collaboration between all the members of the Networked Biomedical Research Center for Hepatic and Digestive Diseases (CIBERehd), Roche and ABL. It is funded with the CDTI MINECO IDI 20110115. Comparison with the current technologies The scientific community has achieved major steps in the study of hepatitis C, especially in the development of new inhibitors, such as sofosbuvir and simeprevir. The combination of these new drugs has reached cure rates up to the 90 per cent in controlled clinical trials, without using the classic treatment of interferon (which causes many side effects such as depression and fever). However, the response to the new antiviral inhibitors is different in each genotype and subtype of the HCV virus. For that reason, Dr. Esteban Mur alerts that <span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', </td></tr></table>comunica@vhir.org (VHIR)Mon, 16 Feb 2015 00:00:00 GMTThe 3rd DiR-Guàrdia Urbana race will raise funds for research in child cancer (12/02/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=22&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0022\2015_0022_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The third edition of the DiR-Guàrdia Urbana race will take place in the Avinguda Diagonal, in Barcelona, on May 31st. Participants will run 10km of the entire Diagonal, with two messages: “for you maybe is just a race, but for them is their life” and “run and help us to investigate for children with cancer”. Part of the funds collected in the race will be donated to the Translational Research in Child Cancer group at Vall d’Hebron Institute of Research (VHIR). The race will start at 8.30 AM at Palau Reial and the finish line will be located at Passeig Garcia Faria. Registrations are already open on www.dir.cat and in any of the gyms of the group. The mission of the Translational Research in Child Cancer group is to improve the diagnosis and treatments available for these diseases. </td></tr></table>comunica@vhir.org (VHIR)Thu, 12 Feb 2015 00:00:00 GMTInterarts and VHIR publish the results of the DECIDES ESPAÑA project's assessment (10/02/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=21&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0021\2015_0021_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> DECIDES ESPAÑA has just published on its website the Assessment on access to sexual and reproductive health rights for women in reproductive age of migrant origin in Spain, and an operational guide. One of the most important results of this assessment, in which have participated members of the Infectious Diseases group at Vall d’Hebron Institute of Research (VHIR), is the suitability of developing new educational and informative materials on affective sexual and reproductive health integrating the approach of equity, gender and cultural specificities. The study, presented in Barcelona on the 18th of December, 2014, is part of the activities within the project DECIDES ESPAÑA, implemented by Interarts and VHIR to improve equity in the access to and exercise of sexual and reproductive rights of young and women of migrant origin in Spain. The assessment has been developed by a multidisciplinary group of professionals under the leadership of the Unidad de Salud Internacional Drassanes-Vall d'Hebron (PROSICS Barcelona). The materials suggested in the assessment will also be developed within the framework of DECIDES ESPAÑA, co-funded by the Financial Mechanism of the European Economic Area (EEA Grants) which aims at contributing to the reduction of economic and social inequalities, and strengthening links between donor (Iceland, Liechtenstein and Norway) and beneficiary countries (17 EU Member States). The Plataforma de ONG de Acción Social is the Operational Unit of the Programa de Ciudadanía Activa (Active Citizenship Programme) endowed with EUR 4.6 million to support the contribution of NGOs to social justice and sustainable development. Follow on Twitter: @Ciudadania_Act #CiudadaníaActiva and Facebook: Programa de Ciudadanía Activa. </td></tr></table>comunica@vhir.org (VHIR)Tue, 10 Feb 2015 00:00:00 GMTThe AECC grants a study on child cancer at VHIR (09/02/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=3&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0003\2015_0003_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Spanish association for cancer research (AECC) in Catalonia gave, on Thrusday, 5 one of the 5 grants of the institution to Dr. Aroa Soriano, member of the Translational Research in Child Cancer group at Vall d’Hebron Institute of Research (VHIR). Her study aims to determine the contribution of the extracellular kinase 5 (ERK5) in the aggressiveness of neuroblastoma, which is the most common solid type of tumor among children. According to Dr. Soriano, “the results of this project will be useful to obtain a biomarker of response to certain groups of patients that could response to the therapy based on the inhibition of the ERK5 kinase activity". The recent development of pharmacological inhibitors of ERK5 has positioned this kinase as a therapeutic target in many cancers among adults. However, it has never been analyzed in the case of child cancer. The prognosis of children with neuroblastoma is excellent in low risk patients, but worse in other stages. In fact, in the last 20 years, the survival of patients in the middle and high stages of the disease has not improved significantly and is among the 30 and 50%. For that reason, Dr. Soriano explains that “due to the existence of multiple mechanisms that cause the resistance to chemotherapy, and to the failure of current treatments, new therapeutic strategies are needed to treat the patients more effectively”. The project duration is 2 years, has been granted with 20,000 euros and will be developed in collaboration with the Protein Kinases and Signal Transduction in Neuronal Cells research group of the Universitat Autònoma de Barcelona (UAB). The AECC in Catalonia has granted a total of 5 Catalan research projects with 100,000 euros. </td></tr></table>comunica@vhir.org (VHIR)Mon, 9 Feb 2015 00:00:00 GMTDiscover the winners of the 4th VHIR' scientific images contest (06/02/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=20&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0020\2015_0020_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> We have the winners of the fourth edition of the VHIR’ scientific images contest! As it happened in last editions, it wasn’t easy for the jury to choose among the pictures presented, which stand out for their creative, original and analytic point of view, as well as for their shapes and colors. The best pictures are already decorating VHIR’s facilities and soon some of them will take part in an exhibition with the best of the four editions of the contest. We invite you to see all the pictures on our Facebook profile (click here). Once again we want to thank VHIR’s researchers for participating and sharing the pictures which represent the day-to-day of our biomedical research. See you on the next edition! </td></tr></table>comunica@vhir.org (VHIR)Fri, 6 Feb 2015 00:00:00 GMTHelp Dr. Cristina Sole to run the BCN Marathon for Lupus (04/02/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=19&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0019\2015_0019_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Cristina Solé, researcher of the Systemic Diseases group at Vall d’Hebron Institute of Research (VHIR), will run the 37th Edition of the&nbsp; Zurich Barcelona Marathon with a great challenge: to raise funds for research on Lupus disease. With this aim, she has created a challenge in migranodearena.org, that will be open until the day of the race, on March 15. The members of the research line in lupus at VHIR, led by Dr. José Ordi-Ros, together with the collaboration of the Catalan Lupus Foundation and the Albert Bosch Foundation, work heavily to conduct clinical trials, design and apply protocols for the treatments, and investigate the possible causes, new therapies and biomarkers to fight against the disease. The cause of Lupus is unknown, its evolution is uncertain and researchers have not found the cure yet. Each Lupus is different but, commonly, the antibodies use to attack the own organism instead of protect it against external agents. Patients with lupus feel very tired all day, suffer from the joints and many of them present skin injuries, or even severe injuries in many vital organs such as the kidney. With the challenge created in migranodearena and her effort, Dr. Solé aims to raise 2,000 euros. All funds collected will go directly to the research on these diseases that affect, only in Catalonia, more than 6,000 people. Collaborate </td></tr></table>comunica@vhir.org (VHIR)Wed, 4 Feb 2015 00:00:00 GMTMembers of the BERENICE consortium met at Vall d'Hebron for the 3rd General Assembly (02/02/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=18&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0018\2015_0018_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Members of BERENICE consortium about Chagas' disease, led by Dr. Israel Molina, researcher of the Infectious Diseases group at Vall d’Hebron Institute of Research (VHIR), had their Third General Assembly on the 28th January 2015, in Barcelona. The main objective of the meeting was to discuss with its eight European and Latin American partners the progress of the project, which began on 1st September 2013, for a period of 5 years. BERENICE is funded under the European Community's 7th Framework Programme with the aim to obtain a more effective, better tolerated and cheaper formulation of a drug with trypanocidal activity to cure Chagas disease. During the meeting, the partners shared updates on project progress to date and discussed how to move forward both at Work Package and Consortium levels. The project is in a key moment to decide the final formulation to conduct clinical trials in humans. It is designed as an international multicenter clinical trial which will take place in the facilities of the Vall Hebron University Hospital and other sites such as Argentina, Bolivia or Mexico. The encapsulation of benznidazole using nanotechnology will generate a new drug delivery system. This new approach will allow a release of medication directly into the intracellular space, therefore increasing tissue drug concentration and avoiding side effects. A better toxic profile will be obtained because of the reduced amount of benznidazole used. </td></tr></table>comunica@vhir.org (VHIR)Mon, 2 Feb 2015 00:00:00 GMTResearchers identify a gene associated to higher survival from sepsis due to pneumonia (30/01/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=17&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0017\2015_0017_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers from the European Society of Intensive Care Medicine (ESICM) have identified a gene located in chromosome 5 that is associated to higher risk of survival from sepsis due to pneumonia or intra-abdominal infection contracted outside the hospital. Dr. Jordi Rello, head of the Clinical Research and Innovation in Pneumonia and Sepsis (CRIPS) group at Vall d’Hebron Institute of Research (VHIR), led the Spanish participation in this study published recently in The Lancet. The aim of the research was to determine whether the genetic factors contribute to the progress of the disease. With this purpose, researchers conducted the first genome-wide association study carried out in patients admitted to intensive care units with sepsis due to pneumonia. They analyzed up to 1.500 patients of whom the 23 per cent died within the intensive care unit admission. Among the results obtained, scientists identified this gene of the chromosome 5, called FER, that is carried by nearly the 20 per cent of the European population. The genetics of these people protects them from the progress of the disease and improves their response to the current treatments. Thanks to this discovery, Dr. Rello reports that they could “develop biomarkers for risk stratification, as well as potential novel targets for therapy or prevention of the complications”. Pneumonia is the main cause of severe sepsis, which is the inflammatory response of the body to the infections. Despite the latest advances on research, Dr. Rello assures that the mortality rate of sepsis due to pneumonia has never fallen from the 20 per cent. </td></tr></table>comunica@vhir.org (VHIR)Fri, 30 Jan 2015 00:00:00 GMTVall d'Hebron hosts an exhibition on rare diseases research (29/01/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=13&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0013\2015_0013_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The maternal-pediatrics area of the Vall d’Hebron University Hospital will host from the 2nd to the 19th of February the exhibition Menys rares (‘less rare’ in English), dedicated to research on rare diseases. The exposition is organized by the Catalan association of scientific communication (ACCC), the Center for Biomedical Network Research of Rare Diseases (CIBERER) and the National Genome Analysis Centre (CNAG). Menys rares was opened in 2014 at the Sagrada Familia Library in Barcelona, and includes a summary of the research carried out at Vall d’Hebron Institute of Research (VHIR) in more than one hundred rare diseases, in which Vall d’Hebron is the leader in Spain. The exhibition shows the reality of these diseases that include between 5,000 and 7,000 different types of pathologies. The European Union classified as ‘rare diseases’ those that affect less than 1 individual out of 2,000, according to orpha.net. The origin of most of these diseases is genetic and there is a lack of medical and scientific knowledge about them. For that reason, the research of therapies and drugs is essential.&nbsp; In Spain there are several research groups that work together through entities such as CIBERER (from the Instituto de Salud Carlos III), or CNAG. As 2013 was the International Year on Rare Diseases, both institutions, together with the ACCC, decided to promote the research carried out by their scientists in these diseases. The aim of the exhibition is to show to the society what rare diseases are really all about, and what researchers are currently doing to combat their effects. With particular cases, such as Lowe, <a style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-style: normal; font-weight: bold; color: </td></tr></table>comunica@vhir.org (VHIR)Thu, 29 Jan 2015 00:00:00 GMTAmics de Les Arts and Trepitja Garrotxa give more than 43,000€ for research in children diseases (28/01/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=12&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0012\2015_0012_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Catalan meat company Noel Alimentària, through its foundation called ‘Albert Bosch’, has given the 43.508 euros raised in 2014, for the research in children diseases at Vall d’Hebron Institut de Recerca (VHIR). The funds were collected in the Trepitja Garrotxa race and two concerts of Els Amics de les Arts, who have played today for the children with cancer at Vall d’Hebron Hospital. The Catalan band rose up to 38.000 euros in two benefit concerts, hosted in Olot and Sant Cugat del Vallès, and organized by the Albert Bosch Foundation in order to contribute to child cancer research at VHIR, headed by Dr. Sánchez de Toledo. Beside these concerts, during 2014 the Foundation organized several activities in La Garrotxa region, such as the first ultra-resistance race ‘Trepitja Garrotxa’, with more than 80 participants and 5.650 euros collected. The Albert Bosch Foundation was created in 2004 by Noel Alimentària, with the aim of promoting medical research for child diseases and lupus. </td></tr></table>comunica@vhir.org (VHIR)Wed, 28 Jan 2015 00:00:00 GMTIronman for child cancer (27/01/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=11&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0011\2015_0011_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Alberto, Sergio, Víctor, Chelo and Ilde are the brave athletes who will run, swim and cycle the Lanzarote Ironman that will take place on May 23rd. They will compete with a great objective: to raise funds to advance in child cancer research at Vall d’Hebron Institut de Recerca (VHIR). “We aim to transmit our energy and support to all the children who are fighting against cancer”, said Alberto, who opened the challenge in the fundraising site migranodearena.org. They’d like to raise 2,500 euros that will directly go to the Translational Research in Child Cancer group, led by Dr. Josep Sánchez de Toledo at VHIR. The athletes are from León, Valencia and the Canary Islands, they have participated in several Ironman, but they have never visited the Pediatric Oncology Unit at Vall d’Hebron University Hospital. However, they are convinced that they want to contribute to help the weakest and reach the 0 mortality rate in child cancer. The research group at VHIR is dedicated to investigate new treatments and diagnosis methods to combat cancer during childhood. The survival rate to this disease is high, close to the 80%, but some neoplasias show lower rates. In this sense, further research is needed in order to find new therapies that could improve the general prognosis and the survival high-risk patients. </td></tr></table>comunica@vhir.org (VHIR)Tue, 27 Jan 2015 00:00:00 GMTDr. Ariadna Laguna has been granted by the Tatiana PGB Foundation to study Parkinson's disease (23/01/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=9&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0009\2015_0009_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Tatiana Pérez de Guzmán el Bueno Foundation has granted with one out of the eight neuroscience research grants Dr. Ariadna Laguna, researcher of the Neurodegenerative Diseases group at Vall d’Hebron Institute of Research (VHIR). The project, entitled “Study of the transcriptional profile in a sub-group of prodromal patients with Partinson’s disease”, will last 3 years and has been funded with 40,000 euros. The aim of the study is to identify molecular pathways, genes and microRNAs deregulated in two types of patients who have not displayed yet the motor symptoms, but have already suffered other changes that precede the onset of the disease. In order conduct the study, Dr. Laguna will carry out a cutting edge RNA sequencing technique from isolated neurons of post-mortem brain tissue from both groups of patients. With the results of the study, VHIR researcher expects that “we could better understand the etiology and pathogenesis of the disease and correlate the transcriptional changes with the clinical and neuropathological data”. Despite the latest advances in Parkinson’s disease research, the only treatment available is symptomatic and is yet far away to avoid the onset of the disease and its progression. </td></tr></table>comunica@vhir.org (VHIR)Fri, 23 Jan 2015 00:00:00 GMTVHIR researchers launch a bank of primary immunodeficiencies samples (21/01/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=8&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0008\2015_0008_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Infection in Immunocompromised Pediatric Patients group and the Immunology group at Vall d’Hebron Institute of Research (VHIR) have started to collect blood samples from patients with primary immune deficiencies and their relatives who also participated in the Immunology Bank of the HUVH Biobank. The aim of the groups is to become the biobank of reference in these diseases in Catalonia. VHIR researchers will collect samples of the 3 types of patients that they treat in the Pediatric Infectious Diseases and Immunodeficiencies Unit (UPIIP): patients with a clinically compatible case and genetic confirmation; patients with primary immunodeficiencies in which the gene that causes the disease is still unknown, and patients with an unknown type of immunodeficiency. All the samples will be collected during routine blood tests, and with parental consent. In this case, researchers will also offer to the patients’ relatives the opportunity of being studied in order to carry out genetic studies with more diagnostic ability. With the samples collected in a standardized model, researchers will investigate these diseases, optimize the diagnosis and offer genetic counseling to the closest relatives, in collaboration with the Clinical Genetics Area at Vall d’Hebron hospital. This project has the support of the Catalan association of patients with immunodeficiencies (ACADIP), the BCN-PID Foundation and the fundraising campaign "tots amb Didac", that has raised over 43,000 euros for the research at VHIR in these rare diseases. Primary Immunodecifiencies at Vall d'Hebron <p style=" text-align: left; text-indent: 0px; padding: 0px </td></tr></table>comunica@vhir.org (VHIR)Wed, 21 Jan 2015 00:00:00 GMTSchizofrenia, major depression and bipolar disorder share genetic risk factors (20/01/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=6&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0006\2015_0006_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Psychiatric Genomics Consortium, from which are members researchers of the Psychiatry, Mental Health and Addictions group at Vall d’Hebron Institute of Research (VHIR), have published a study that concludes that psychiatric disorders such as schizophrenia, major depression and bipolar disorder share genetic risk factors and variations associated with the immune system. The study has been published this week in Nature Neuroscience. Researchers carried out a genome-wide association study to analyze the genetic profile from over 60,000 participants from the different countries of the consortium. Once they compared the results, they discovered that the three adult psychiatric disorders implicate neuronal, immune and histone pathways. According to Dr. Josep Antoni Ramos-Quiroga, VHIR researcher who has participated in the study, “the knowledge of the molecular pathways involved in these diseases will enable the development of more specific therapeutic targets”. Nowadays, the etiology of these diseases is largely unknown, there is a lack of biomarkers, and the diagnosis is based exclusively in clinical symptoms. VHIR researchers provided data about the attention deficit-hyperactivity disorder (ADHD), because the study also compared the genetic profiles of people with other psychiatric disorders. </td></tr></table>comunica@vhir.org (VHIR)Tue, 20 Jan 2015 00:00:00 GMTAbdominal distension can be corrected by muscular control techniques (15/01/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=5&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0005\2015_0005_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers from the Physiology and Pathophysiology of the Digestive Tract group at Vall d’Hebron Institut de Recerca (VHIR), led by Dr. Fernando Azpiroz, have proved that abdominal distension can be prevented by correcting thoracic and abdominal muscular activity, as the cause is a voluntary muscular response, induced by small changes in the intestinal contents. The study, published in Gastroenterology, is the last phase of a 15 year research that has proved that neither gas, nor the abdominal content are responsible of the abdominal bloat. VHIR’s researchers carried out a prospective study with 45 patients with functional bowel diseases and abdominal distension episodes, which sometimes were asymptomatic when visiting the hospital. “By performing an abdomino-thoracic computed tomography, to see the shape of the abdomen, and an electromyography, to verify muscular activity, we saw that patients with distention have larger thorax filling, with a wall elevation, and anterior abdominal wall protrusion”, explained Dr. Azpiroz. After realizing it was a muscular problem, the researchers instructed the patients (1-3 lessons) on how to revert the situation, relaxing the diaphragm and intercostal muscles, and also contracting the anterior abdominal wall. As a result, patients corrected abdominal distention by reducing the diaphragm’s and intercostal muscles’ activity. Both for diagnosis and for teaching purposes, VHIR’s researchers have been using “a very sophisticated system, precise and expensive, that allows us to control all the variables and show the patients their muscle’s reactions”, says Dr. Azpiroz. This means that now it’s important to validate the system in a controlled trial, and that there is still a lot of work to do in order to simplify the procedure before it can be transferred to clinical practice. Anyhow, the experimental treatment has proved that abdominal distension is under voluntary control and can be reverted. The finding also reveals why patients with abdominal distention usually feel they lack air. What really happens is that they have difficulty to breathe because their thorax is full of air, as it happens with asthmatic and lung emphysema patients, and not oppressed by the abdominal contents as traditionally thought. Abdominal distension is one of the main symptoms of functional gut diseases, such as irritable bowel syndrome, abdominal bloating or functional dyspepsia, and is the reason of nearly 40% of the gastroenterology consultations. VHIR’s researchers observed this muscular change over 5 years ago, after noticing that in patients with distension both gas volume in the bowel and viscera in the abdominal cavity show a slight increase that, by itself, do not justify distension.&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Thu, 15 Jan 2015 00:00:00 GMTDr. Marta Ribases receives one of the American NARSAD grants to study ADHD (14/01/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=4&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0004\2015_0004_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Brain &amp; Behaviour Research Foundation has awarded Dr. Marta Ribases, researcher of the Psychiatry, Mental Health and Addictions group at Vall d’Hebron Institute of Research (VHIR), with one of the National Alliance for Research on Schizophrenia and Depression (NARSAD) grants. The aim of the project, endowed with nearly 65,000 dollars for the next two years, is the identification of biomarkers for Attention Deficit Hyperactivity Disorder (ADHD), through high-throughput next generation sequencing. Specifically, she will compare genome-wide microRNA expression profiles in patients with ADHD and controls. ADHD is the most common childhood onset psychiatric disorder; it affects 6% of children and manifests as symptoms of inattention, hyperactivity and/or impulsivity. The etiology of ADHD is complex, with the involvement of both genetic and environmental factors. According to Dr. Ribases, “given the lack of consistency of results obtained in genetic studies of susceptibility variants, the analysis of biological markers, such as miRNA or gene expression, which can reflect the combined effect of genetic predisposition and environmental risk factors, represents an alternative approach to identify potential risk factors involved in the disease”. NARSAD grants are addressed to young, independent and distinguished investigators in the field of mental health. The grants keep the former name of the Brain &amp; Behaviour Research Foundation, which since 1987 has awarded over 320 million dollars for research projects related to mental illness. </td></tr></table>comunica@vhir.org (VHIR)Wed, 14 Jan 2015 00:00:00 GMTMaria Salvadó has been awarded at the 25th International Symposium on ALS (08/01/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=2&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0002\2015_0002_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Maria Salvadó, neurologist and researcher of the Pheripheral Nervous Diseases group at Vall d’Hebron Institute of&nbsp; Research (VHIR), won the Scientific Poster Prize at the 25th International Symposium on Amyotrophic Lateral Sclerosis (ALS). The researcher of the group led by Dr. Josep Gámez presented in a poster the results of the role of the microloglia CX3CR1 gene as a modifying factor in the progression of the symptoms and the survival of ALS patients. According to one of the members of the jury, Prof. Linda Greensmith, “it was a clearly presented and well conducted study which identified a new genetic factor that influences the rate of disease progression and survival time in patients”. More than 800 international experts participated on December in this symposium which took place in Brussels, in order to present and discuss the latest advances in the fight against ALS. The cause of this disease is unknown and there is no cure or treatment available. It is characterized by the loss of motor neurons which cause rapidly progressive weakness, muscle atrophy and the death of the patients by breathing failure. </td></tr></table>comunica@vhir.org (VHIR)Thu, 8 Jan 2015 00:00:00 GMTVHIR in 2014 (31/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=277&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> We end a year full of scientific landmarks that will help to improve people’s health. ¿Do you want to read some of the main discoveries of VHIR researchers in 2014? We have created a Storify with some of the best news, tweets, pictures and videos of the year. To read it properly and on full screen, click on the following link: VHIR in 2014 Thanks to all of you who have made possible this great 2014. We wish you a happy new year!&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Wed, 31 Dec 2014 00:00:00 GMTVHIR's director talks to the media about the past, present and future of the Institute (23/12/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=276&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0276\2014_0276_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> VHIR's Director, Dr. Joan Comella, was interviewed in several media to talk about the present, past and future of Vall d'Hebron Institute of Research (VHIR), coinciding with its 20th anniversary. Dr. Comella remembered the first years of research at Vall d'Hebron Campus, with all the problems and the illusion of those years, but also the hard work of all of the researchers and doctors that helped to begin the Institute. He also talked about the present, the good results and the best strategies to keep improving in the future. "We can only ask the researchers to be good doing research, not to be heroes", he reported to the journal Ara, highlighting that one of the functions of the Institute is to make all the work to help the researchers, so they only should do science. In the same interview, Dr. Comella confessed that "being the Director of the Institute is the best of my professional career", and showed his optimism regarding the potential of VHIR in the future. Dr. Comella was also interviewed in 8TV and BTV, together with VHIR researchers such as Dr. Simó Schwartz, first director of research at Vall d'Hebron, and Dr. Rafael Simó, president of the VHIR's Internal Scientific Council. Dr. Anna Meseguer, deputy director of basic and translational research at VHIR, also talked about the 20th anniversary of the centre, in this case in the webpage of the Barcelona city council. </td></tr></table>comunica@vhir.org (VHIR)Tue, 23 Dec 2014 00:00:00 GMT'Enzyme' will donate a Euro for each click to research in child cancer this Christmas (22/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=273&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0273\2014_0273_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Enzyme Advertising Group supports the research in child cancer at VHIR with an internet campaign that will raise 1 Euro for each click to the Christmas card on their web page. Enzyme is a professional services firm with international presence that provides consulting and technology advice joining together new challenges and business models. For each visit made to the Christmas card online, Enzyme will give 1 Euro to the A. Bosch Foudation that has supported VHIR’s work for many years, especially that related to research in child cancer. The firm will also raise 1 Euro for each ‘Like’ on their Facebook page, and for every new follower on their Twitter and Linkedin accounts. You have time to click for donations until the 24th of December. </td></tr></table>comunica@vhir.org (VHIR)Mon, 22 Dec 2014 00:00:00 GMTDr. Bruno García will sail around the world with VHIR's logo on his boat (22/12/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=275&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0275\2014_0275_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> His name is Bruno García, Doctor Bruno García, cardiologist and member of the research groups on Cardiovascular diseases, and amateur sailor. In not much more than a week he will part to go around the world on a boat with his brother, Willy, as they are one of the 8 teams that participate on the Barcelona World Race (BWR) that starts in Barcelona on the 31st of December. He is 47 years old and this will be his second BWR. His brother is a jeweler and is 42. They are both going to share three months or more, depending on if they make it to the end, a sports and human adventure on the boat ‘We are water’, the name of the foundation that provides logistic support in this participation. But Bruno has wanted to add one more brand to his boat, the logo of the Vall d’Hebron Institute of Research (VHIR), to raise awareness among those who follow the regatta during the following months about the importance of research in cardiovascular diseases, especially in congenital heart diseases and the ones that affect children. “Combining my adventure with the VHIR will help spread the message of the importance of congenital heart diseases, of cardiovascular pediatric problems and, in general, of all research in the heart area”, points out Bruno as he presents his boat to the media, as well as his reasons to enter this adventure, together with the synchronized swimming Olympic team, that has sponsored the ‘We are water’. “We are water and the VHIR are two messages totally in line with solidarity and awareness”, says Dr. García while holding a catheter in his hand showing it to the cameras as a symbol of uniting profession and vocation. His little brother observes him while they both answer questions about how the cohabitation will be in the next three months, while sailing the 23 thousand nautical miles of the race, non-stop. It is going to be worth it and from the VHIR we will follow their journey. And remember, if Bruno is capable of sailing around the world to raise awareness to people, everyone can help on their own way to research, in this case at VHIR, through the donations web page yoinvestigo.org. </td></tr></table>comunica@vhir.org (VHIR)Mon, 22 Dec 2014 00:00:00 GMTVHIR wishes you Season's Greetings and a Happy New Year (19/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=271&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0271\2014_0271_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Vall d’Hebron Institute of Research (VHIR) sends Season’s Greetings through the institute’s new mascot, The VHIR, who will help the center to spread its research to the society more easily. The mascot has switched to Christmas mood to wish everyone Seasons's Greetings and a Happy New Year 2015. VHIR, the mascot, that was presented for the first time during the celebration of the 20th anniversary of the institute and, from 2015 will be the image of the outreach activities of the institution. The mascot VHIR and this card are a common project between La Casa de Carlota and Vall d’Hebron Institute of Research. La Casa de Carlota is a design studio composed by disabled designers and young design students, who work to unite talent, normalize and integrate into the labor market every individual’s unique capacities and not their disabilities.  Merry Christmas and a Happy New Year from VHIR </td></tr></table>comunica@vhir.org (VHIR)Fri, 19 Dec 2014 00:00:00 GMTVHIR and Interarts present the results of a Project to ensure sexual and reproductive rights of immigrant population in Spain (19/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=272&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0272\2014_0272_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers from Vall d’Hebron Research Institut (VHIR) and the Programa de Salut Internacional de l’Institut Català de la Salut (PROSICS) along with Interarts, presented the results of the “Diagnosis of the access situation to sexual and reproductive rights (SRR) of migrant women of fertile age in Spain”, in the frameworks of the project DECIDES ESPAÑA. The aim of this initiative is to improve equity in access to and exercise of sexual and reproductive rights of young and women of migrant origin in Spain. During the presentation, Gemma Garreta, member of VHIR-PROSICS, exposed the main conclusions of the study: the need to involve men in issues of sexual and reproductive health, and not only women; the advisability of providing tools to health professionals to allow them to create a relation of empathy and trust with migrant women patients and the need to develop formative and outreach materials about sexual and reproductive health that integrate an equity point of view. In this regard, Jordi Gómez, doctor responsible of the Unit of tropical and international health at Vall d’Hebron, explained that “the study we carried out suggests that social determinants of migrant women are a key to understand their access to the health system regarding sexual and reproductive health”. This, according to Gómez, guides the development of the project, which works “improving the attention provided by healthcare professionals through training, as well as, in a second phase, raising awareness of population”. After presenting the results, the meeting closed with a round table conference, moderated by Hakima Ouaarab, from PROSICS-Vall d’Hebron. This project is co-funded by the Financial Mechanism of the European Economic Area (EEA Grants) which aims at contributing to the reduction of economic and social inequalities, and strengthening links between donor (Iceland, Liechtenstein and Norway) and beneficiary countries (17 EU Member States). The Plataforma de ONG de Acción Social is the Operational Unit of the Programa de Ciudadanía Activa<span style=" font-size: 8pt; font-fam</td></tr></table>comunica@vhir.org (VHIR)Fri, 19 Dec 2014 00:00:00 GMTThe Spanish Parkinson Federation recognizes a study by Dr. Vila as the best research paper (18/12/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=267&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0267\2014_0267_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Miquel Vila, head of the Neurodegenerative Diseases Group of the VHIR, and member of CIBERNED, has been recognized as the best research paper in the VII edition of the Spanish Parkinson Federation (FEP) awards. The jury recognized the article ‘Lewy Body Extracts from Parkinson Disease Brains Trigger a-Synuclein Pathology and Neurodegeneration in Mice and Monkeys’, published last march in the scientific journal Annals of Neurology and presented by Dr. Miquel Vila, among the 21 articles presented coming from research centers and hospitals from all over Spain. The same scientific journal, Annals of Neurology, and its editorial board had already awarded Dr. Vila’s article two months ago, as best article of 2014. The study shows that pathological forms of the alfa-synuclein protein present in the brain of deceased Parkinson Disease (PD) patients were capable of initiating a PD-like pathological process in mice and primates. For the authors, these findings provide new information on how the disease is initiated and amplified. For Dr. Gurutz Linazasoro, president of the FEP jury, “the work can explain the mechanism of neuronal degeneration and the progression of the symptoms. The most direct potential consequence is the identification of new targets for neuroprotective therapies”. Moreover, he assures that “we have to stress that the work is fruit of the collaboration effort of different groups, national and international, and makes an example of the way of making big science in the 21st century”. </td></tr></table>comunica@vhir.org (VHIR)Thu, 18 Dec 2014 00:00:00 GMTKilometric donations (17/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=266&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0266\2014_0266_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Recovering from an IronMan competition can be a challenge by itself but for Chronic Fatigue Syndrome (CFS) patients the real challenge is every day life. The consequences of participating in one of the most physically demanding races are very similar to the symptoms that CFS patients experiment. This illness affects up to 3% of the population. With this idea in mind, 8 participants from the IronMan race in Barcelona have started the #IMHeart project. Using a Smartphone app kilometers will be accumulated whenever the users are exercising, later those kilometers generated will be ‘donated’ to CFS research projects. The kilometers covered will be given to the study coordinated by Dr. Jesús Castro, from the Chronic Fatigue group at VHIR, headed by Dr. José Alegre, titled “CFS and fibromyalgia in teens: emergent entities that determine academic failure and deterioration of life quality”. The project is drove in collaboration with several national and international research and university centers such as Hospital Sant Joan de Déu, Centro Médico Delfos, Hospital Clínic and University of Bristol (UK). The ‘Associació Catalana d’Afectats de Fibromialgia, SFC I SQM’ (ACAF) also gives support to the cause. For participating in the donation it is necessary to get registered in the web: http://app.iwopi.org/login, and download the Runkeeper app for Smartphone. Once some distance is covered, you can donate the kilometers through the iWOPI web to the CFS project. Through the iWOPI platform, the kilometers given by the donors will be accumulated. The challenge thrown is to achieve 150.000 km in three months. Those kilometers (or miles) can be earned either running, walking, swimming or riding a bike. The ultimate objective is to be on the move for those who cannot do it every day. </td></tr></table>comunica@vhir.org (VHIR)Wed, 17 Dec 2014 00:00:00 GMTAmics de Les Arts raise more 40,000 euros for child cancer research (15/12/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=263&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0263\2014_0263_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Catalan band ‘Els amics de les Arts’ has raised 40 thousand Euros in two benefit concerts organized by Albert Bosch Foundation in order to contribute to child cancer research in Vall d’Hebron Institute of Research (VHIR), group headed by Dr. Sánchez de Toledo. The group threw its second and last benefit concert last Thursday in Sant Cugat’s Teatre-Auditori. They also had some friends joining them on stage, such as Joan Dausà, Roger Mas, Cybee, Els Catarres, Blaumut and Mamzelles. Els amics de les Arts have thanked trough their web the unselfish collaboration they have received saying “all the work that means organizing this kind of concert pays off when you find yourself on stage singing someone else’s song that you love, or when you hear one of your songs but with a voice that’s not your own, or when your fingers are literally trembling accompanying someone who has written songs that are very important for you”. VHIR’s researchers were invited by the band to this second concert which was full of emotion and complicity between the band and the invited musicians. The first benefit concert was in Olot, at Braus Square, where the band presented its new album ‘Només d’entrar hi ha sempre el dinosaure’. All the money raised during the concerts will go to the three research lines of VHIR’s Translational Research in Child Cancer Group, with whom Foundation A. Bosch is collaborating in order to get better diagnosis and therapies. Foundation A. Bosch was created in 2004 by Noel Alimentària, with the aim of promoting medical research for child diseases and lupus. </td></tr></table>comunica@vhir.org (VHIR)Mon, 15 Dec 2014 00:00:00 GMTThe editor-in-Chief of 'The Lancet' closes Vall d'Hebron 18th Annual Conference (12/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=262&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0262\2014_0262_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The editor-in-Chief of the prestigious scientific journal The Lancet, Dr. Richard Horton, has come to Vall d’Hebron to give the closing speech of the Vall d’Hebron Universitary Hospital 18th Annual Conference which ended this Friday, December 12th. With an enthusiastic speech with references to Picasso and Salvador Espriu, Horton has reflected on the challenges of the future, that in his opinion are global vision of health, science, society, solidarity and sustainability. The conference has ended the 8th VHIR Scientific Conference. Before the The Lancet’s editor conference, VHIR’s director, Dr. Joan Comella, has presented the Institute’s annual results. He has highlighted the good results on scientific production that puts VHIR’s researchers in first-line research, with an accumulated impact factor during 2014 of 3.500. He has also presented the great economic results of the centre, obtained thanks to competitive calls, clinical trials, agreements with industry and donations. The hospital’s manager, Dr. José J. Navas, has praised the daily work carried out by VHIR’s researchers to improve people’s health and life quality, and has remarked the importance of innovation to speed up this goal. VHIR grants Once again, the Institute has awarded the predoctoral grants during the Annual Conference, but for the first time in this 18th edition, ‘VHIR’s friends’ have participated in the ceremony. The Institute’s donors will fund for 3 years the predoctoral training of Casandra Riera, researcher from the Bioinformatic Group, and Luz Jubierre<span style=" font-size: 8pt</td></tr></table>comunica@vhir.org (VHIR)Fri, 12 Dec 2014 00:00:00 GMTOpening of the VHIR's 8th Scientific Conference (11/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=261&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0261\2014_0261_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Today has started the 8th VHIR’s Scientific Conference. During two days, 41 physicians in training, 36 predoctoral researchers, 9 postdoctoral researchers and 9 researchers in nursing will present what they are currently investigating at Vall d’Hebron Institute of Research (VHIR). On this edition the sessions will take place in different places: the Auditorium of the 10th floor of the hospital will host the first part of the predoctoral sessions and all the nursing presentations; the second part of the predoc sessions will take place at the conference room of the Collserola building; the conference room of the ground floor of the hospital will host the presentations of the physicians in training; and the auditorium of the Pavelló Docent building will host the presentations of the postdoctoral researchers. The best presentations will be awarded at the 18th Annual Conference, that will take place on Friday at the Pavelló Docent. On the ceremony, will be also recognized the winners of the VHIR predoctoral grants, the ‘VHIR friends’ predoctoral grants, and the post-mir grant by the Obra Social ‘la Caixa’. The annual lecture will be pronounced by the editor-in-chief of the prestigious scientific journal The Lancet, Dr. Richard Horton. The title of his speech is “Science and charity: reflections on the purpose of medicine and the meaning of health”. - Program of the 8th VHIR Scientific Session <p style=" text-align: left; text-indent: 0px; padding:</td></tr></table>comunica@vhir.org (VHIR)Thu, 11 Dec 2014 00:00:00 GMTWorld experts in endoscopic surgery meet in Vall d'Hebron (10/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=260&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0260\2014_0260_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The World Institute for Digestive Endoscopy Research (WIDER-BCN) from Hospital Universitary Vall d’Hebron has organized a two day International Course: Natural Orifice Translumenal Endoscopy Surgery (NOTES) dedicated to transluminal endoscopy trough natural orifices. Over 130 doctors, surgeons and researchers from all over the globe participated in this 8th edition, directed by WIDER’s leader, Dr. José Ramón Armengol, and Doctors Manuel Armengol and Antonio J. Torres García. The meeting has become the world’s most outstanding forum about advanced endoscopic and transluminal surgery. WIDER center was created in 2008, as an agreement between Generalitat de Catalunya, Obra Social “la Caixa”, Vall d’Hebron Universitary Hospital and VHIR to encourage and promote research in endoscopic surgery and implement a specific and autonomous program inside VHIR’s structure for this area. Specifically, research in endoscopic and surgery technology, experimental endoscopic research using NOTES methodology, clinical innovation research and training in medical-surgical digestive endoscopy in the different specialties. WIDER institute, which is led by Dr. José Ramon Armengol, aims to clinical application, animal experimentation and national and international diffusion of their activities. One of these activities is the NOTES Course that in its 8th edition offered presentations about simulations such as Single port access, NOTES experimental, NOTES clinic, NOTES applied to obesity and transrenal surgery. In endoluminal endoscopy new diagnostic alternatives were presented in bilipancreatic diseases, and in endomulnial therapeutic specialty Poem’s new techniques with Acalasia treatment and new techniques in tumor resection. In this edition two surgeries were broadcasted, one of them from the clinical side, endoscopy, Acalasia patients and tumoral and polypoid deformation of the digestive tract. The other video was broadcasted from VHIR’s ‘Animal Facility’, very sophisticated bile and pancreatic drainage interventions using ecoendoscopy. All the patients who were operated have evolved without complications and were sent home (4 acalaseis, 6 resections and sewing of the gastric and colonic wounds). The course’s first night a dinner-symposium was thrown in CosmoCaixa, presided by the Health Consellery representative, Joaquim Casanova, and La Caixa’s representative, Enric Banda. In this event two endoscopy experts, Kiyokazu Nakajima and Sergey Kantsevoy, spoke about non-sedated colonoscopy and automatic use of CO2 in endoluminal surgery and esdoscopy. </td></tr></table>comunica@vhir.org (VHIR)Wed, 10 Dec 2014 00:00:00 GMTThe Chronic Fatigue group presents the results of a clinical trial and a biological study with antioxidants (09/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=259&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0259\2014_0259_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Chronic Fatigue group at Vall d’Hebron Institute of Research (VHIR), led by Dr. José Alegre, presented together with the Catalan company VITAE the preliminary results of a clinical trial and a biological study with Reconnect®, based on the combination of antioxidants Coenzyme Q10 + NADH, with the aim of improving the symptoms of the Chronic Fatigue Syndrome (CFS).  The clinical trial has demonstrated that the synergetic combination of both natural antioxidants improves the symptoms of the disease and also recovery of biomarker parameters. VHIR researchers conducted the Phase II, double blinded and randomized clinical trial, in 73 patients diagnosed with chronic fatigue syndrome at Vall d’Hebron University Hospital. During 8 weeks, half of them were given CoQ10 + NADH and the other half, placebo, in order to compare the effect of the drug on the cardiac adaptations of patients with chronic fatigue. Furthermore, researchers also measured the intensity of fatigue, pain and sleep problems, before and after the treatment. The results have been recently published in the journal Antioxidants &amp; Redox Signaling. Dr. Jesús Castro, principal investigator of the Chronic Fatigue group, highlights five benefits of the study: “patients who received this combination of antioxidants showed a significant fatigue reduction, an increase in antioxidant levels and recovery of energy and mitochondrial function in ATP form, an increase of synthase citrate enzyme and a reduction in oxidized lipids; all of them key factors that can contribute to the illness symptomatology”. The next step for VHIR’s researchers and VITAE Co. will be to increase to 300 CFS patients more enrolled in the clinical trial from the Chronic Fatigue Clinical Unit at the Vall d’Hebron Hospital. </td></tr></table>comunica@vhir.org (VHIR)Tue, 9 Dec 2014 00:00:00 GMTThe loss of the gene RHOA contributes to the progression of colorectal tumors and metastasis (05/12/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=258&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0258\2014_0258_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers of the Oncology Molecular group from CIBBIM- Nanomedicine at Vall d’Hebron Institute of Research (VHIR) have discovered that the loss of a gene, called RHOA, enhances tumor progression and metastasis in colon and rectal cancer. The study also reveals the mechanism of action of this gene, whose role is completely different in other types of cancer. The results have been published in Nature Communications. The main author of the study, Dr. Diego Arango, has studied the role of RHOA since 2005, when he discovered with another international research group that it was one of the genes that presented more differences in its expression between patients with good and poor prognosis. Based on this first study, the aim of the research that now has been published, was to determinate whether the loss of RHOA levels is the cause (or one of the causes) of the poor prognosis of the patients. In order to prove it, researchers inactivated RHOA in the gut of mice that had started the tumorogenesis, which is the process by which cancer is produced. “We discovered that the animals died earlier and had more and bigger tumors”, explained Dr. Arango, head of the Oncology Molecular group, and researcher of the CIBER of Bioengineer, Biomaterials and Nanomedicine. To confirm the results, they also developed in vitro techniques, which proved that the loss of RHOA is associated to major tumor proliferation and cellular differentiation. After discovering RHOA’s function in colorectal cancer tumors, VHIR’s team sought to determine if the gene’s absence also had a similar effect in metastasis. Using a murine study, the researchers detected that RHOA’s inactivation made colon cancer cells more metastatic. According to the researcher, that explains why “in the metastasis samples from patients with colorectal cancer we have found less RHOA expression than in the primary tumors”.&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Fri, 5 Dec 2014 00:00:00 GMTVall d'Hebron's Market and VHIR promote a solidary calendar (04/12/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=257&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0257\2014_0257_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d’Hebron Market has edited a solidary 2015 calendar, and the money collected will be used in heart disease research in Vall d’Hebron Institut de Recerca (VHIR). The calendar costs one euro, and can be bought in any of the market stands. With this action the market workers wanted to do their bit in heart diseases research, as it causes thousands of deaths every year. Overall, there have been produced 2.000 calendars, drown by Mario Tarragó and designed by Jordi Santamaria. Dr. David García Dorado is head of the Cardiovascular Diseases group at VHIR, and works in prevention, diagnosis and treatment of the heart diseases. The researchers also coordinate actions in sanitary education, healthy lifestyle promotion and create new diagnosis and therapeutic tools and new care systems. </td></tr></table>comunica@vhir.org (VHIR)Thu, 4 Dec 2014 00:00:00 GMTBarcelona's Medical Board acknowledges Vall d'Hebron professionals (03/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=256&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0256\2014_0256_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Barcelona’s Medical Board has awarded five Vall d’Hebron professionals with its 2014 Professional Excellence Award: Dr. Fernando Azpiroz, head of the Physiology and Pathophysiology of the Digestive Tract Group of the Vall d’Hebron Institut de Recerca (VHIR), Dr. Francesc Bosch, head of VHIR’s Experimental Hematology Group, Dr. Josep Àngel Bosch, Internal Medecine expert, and member of the Systemic Diseases Group, Dr. Manuel Matas, specialist in Angilology and Vascular and General surgery, and Dr. Marius Morlans, retired Nephrology specialist. The professional association has also recognized the work carried out by the Cardiology Unit in Vall d’Hebron’s Universitary Hospital, headed by Dr. David García Dorado, head of VHIR’s Cardiovascular Diseases Group. Two of VHIR’s group heads have been awarded Dr. Fernando Azpiroz graduated in Medicine and Surgery in 1977, from Universidad de Valladolid. 9 years later he got his PhD from Universidad Complutense de Madrid, and in 2011 he was appointed Professor in Medicine by the Science and Education Ministry. His first experience in Vall d’Hebron was in 1986, as an associated researcher at the Digestive Tract Research Unit. Before he had been doing his residence in Hospital Clínico San Carlos in Madrid, and had also worked for three years as a researcher in Mayo Clinic at Rochester, Minnesota. Nowadays he leads the hospital’s Digestive Unit, and also VHIR’s research group, composed by over 25 professionals. They are doing first line research in fields such as: abdominal distension, microbiota, or irritable bowel syndrome, among others.&nbsp; Dr. Francesc Bosch graduated in Medicine and Surgery from Universitat de Barcelona in 1988. After finishing his residence in Hematology at Barcelona’s Hospital Clínic, he got his PhD in 1997 also from Universitat de Barcelona. His studies about cyclin D1 overexposure in lymphoproliferative syndromes lead him to take a 2 year postdoctoral position at Columbia University, New York. He returned to Barcelona in the year 2000, and 9 years later he was announced Head of the hemathology Unit of Vall d’Hebron, and Head of the Experimental Hematology research Group. The group is formed by over 20 professionals, and leads three research lines: chronic lymphatic leukemia, lymphoproliferative syndromes and myelodysplastic syndromes. </td></tr></table>comunica@vhir.org (VHIR)Wed, 3 Dec 2014 00:00:00 GMT'Wounded memories, rebel bodies' arrives to Terrassa delivered by Dr. Josep Gámez (02/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=255&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0255\2014_0255_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Josep Gámez, head of Vall d’Hebron Institut de Recerca (VHIR) Peripheral Nervous System group, made the inaugural speech of the exhibition ‘Wounded memories, rebel bodies: itineraries against oblivion’. Until December 4th, exhibition room Cima of the patronal Cecot building will hold this exhibition that has toured Spain, showing the nude bodies of people who suffered the disease. The VHIR researcher spoke about the need to establish a comprehensive care system to help these people, who now, decades after overcoming the disease, deal with what is known as post-Polio Syndrome. Nowadays professionals in Vall d’Hebron look after over 200 people with this illness. The photographic exhibition, with images by Bernat Millet, explores poliomyelitis’s memory through the bodies of people who went through the illness, its consequences, and further effects. The exposure’s goal is to raise awareness in society about the illness trough the scars and stories of the people pictured. </td></tr></table>comunica@vhir.org (VHIR)Tue, 2 Dec 2014 00:00:00 GMTVHIR signs an agreement with the Universidad Técnica de Ambato (02/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=251&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0251\2014_0251_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d’Hebron Institute of Research (VHIR) has signed an alliance with the Universidad Técnica de Ambato, in Ecuador, to promote the exchange of professors and students, organize training activities, and aid in the execution of common research projects. Dr. Juan Ángel Recio, head of the VHIR Melanoma Group, and Mileydis Perez, researcher of the same group, will be in charge of monitoring the activities and common projects between the two centers. As a first project, researchers of both centers will study the role in metabolism of the enzymatic complex aldehyde dehydrogenase (ALDH) and the resistance to therapeutic treatments of the tumor stem cells. This research, that will last 3 years, aims to determinate the biomolecular function of the ALDH isoforms in the control of the cellular death of the tumor stem cells in lung cancer and identifying new targets for the treatment of the illness. </td></tr></table>comunica@vhir.org (VHIR)Tue, 2 Dec 2014 00:00:00 GMTVHIR and Interarts begin a project to ensure sexual and reproductive rights of immigrant population in Spain (30/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=253&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0253\2014_0253_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers from Vall d’Hebron Research Institut (VHIR) and the Programa de Salut Internacional de l’Institut Català de la Salut (PROSICS) along with Interarts, presented the project DECIDES ESPAÑA. The aim of this initiative is to improve equity in access to and exercise of sexual and reproductive rights of young and women of migrant origin in Spain. Until October 2015, the experts involved in the project will develop the following activities: an assessment on equity in access to Sexual and Reproductive Health services, whose results will be published on December 18th&nbsp; at the Vall d'Hebron infrastructure; educational materials that will strengthen the cultural competencies of health sector professionals as well as of key actors in this field; 10 training workshops on the use of the educational material by professionals from the health sector; 5 awareness-raising activities geared towards civil society on sexual and reproductive rights and equality in a context of cultural diversity; 8 presentations on the subject&nbsp; in a context of cultural diversity and equality; as well as 1 workshop of audiovisual creation and reflection on this field for young immigrants. The&nbsp; group of professionals on Infectious Diseases from VHIR and PROSICS have over 20 years of extensive experience in the field of intercultural medicine, both at local / national and international level. The project was presented on November 19th at Casa del Mar in Barcelona, at the conference entitled "Women Sexual and Reproductive Rights. A transnational vision of Female Genital Mutilation". DECIDES ESPAÑA is co-funded by the Financial Mechanism of the European Economic Area (EEA Grants) which aims at contributing to the reduction of economic and social inequalities, and to strengthening the relationships between donor states (Iceland, Liechtenstein and Norway) and beneficiary states (17 EU Member States). The Plataforma de ONG de Acción Social is the Operatoring Agency of the Programa de Ciudadanía Activa (Active Citizenship Programme) which is endowed with EUR 4.6 million for the strengthening of NGOs and their contribution to social justice and sustainable development. Follow the Ciudadanía Activa program on Twitter and Facebook. </td></tr></table>comunica@vhir.org (VHIR)Sun, 30 Nov 2014 00:00:00 GMTVHIR and the Innovative Medicine Initiative present the future call for proposals (28/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=252&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0252\2014_0252_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> On the 26th of November, Vall d’Hebron Institute of Research (VHIR), together with the Innovative Medicine Initiative (IMI) held an Infoday. The main objective of this event was to show more in the details all the future call for proposals of the Public Private Partnership. To start with, Dr. Thomas Eichholtz, CSO and Corporate Director of R&amp;D at Almirall, presented the dynamics behind EFPIA and the call for proposals). He was followed by Dr.Eva Molero, CEO at Synapse Research Management Partners, who gave the partipants more details about real IMI projects, and keys to successful participation and management of such projects. Dr. Marta Gomez Quintanilla, Spanish representative in IMI 2 from CDTI, showed the Spanish participation in IMI so far, and also insisted on the need to be more proactive, and participate more actively in future calls and projects. After the coffee break, Dr. Magda Gunn, from the IMI executive office, explained very clearly the rules and framework of IMI 2, giving tips on the dos and donts in the application process. Participants from different research institutes could discuss and exchange over the lunch break. Then, more insight on the future topics to come were given by Dr. Magda Gunn (IMI) together with Dr. Nima Behkami, Strategic Alliance director at MSD. Dr. Farid Bidgoli, MSD Real World Evidence Manager, also gave a bit more detail on the work they are currently carrying on. Finally, a specific session on venture capital closed the day. Dr. Rémi Droller, Managing partner at Kurma Partners, together with Dr. Nima Behkami led toward a discussion on the potential of future businesses supported by VC in the biomedical field. </td></tr></table>comunica@vhir.org (VHIR)Fri, 28 Nov 2014 00:00:00 GMT